Emergent BioSolutions | EBS - Market Capitalization


Emergent BioSolutions reported $370.1M in Market Capitalization this October of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
Akebia Therapeutics USD 427M 297M Dec/2025
ALKERMES USD 8.73B 2.85B Jun/2026
Alnylam Pharmaceuticals USD 24.65B 15.54B Oct/2026
Amarin USD 290M 51M Dec/2025
ANI Pharmaceuticals USD 1.88B 133M Jun/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Coherus Biosciences USD 172M 19M Dec/2025
Emergent BioSolutions USD 125M 51M Dec/2023
Exelixis USD 18.99B 5.45B Oct/2026
Glaxosmithkline GBP 109.29B 9.36B Mar/2026
Heron Therapeutics USD 238M 7M Dec/2025
Ionis Pharmaceuticals USD 13.1B 642M Jun/2026
Lexicon Pharmaceuticals USD 418M 73M Dec/2025
Lonza CHF 39.68B 980.61M Jun/2025
Merck USD 372.93B 55.56B Oct/2026
Nektar Therapeutics USD 2.12B 1.26B Mar/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Pacira USD 1.69B 694M Oct/2026
Pfizer USD 138.44B 15.37B Jun/2026
PTC Therapeutics USD 4.94B 1.86B Oct/2026
Sanofi EUR 91.15B 9.12B Jun/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
United Therapeutics USD 23B 2.19B Jun/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024